Technical Analysis for BEAM - Beam Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| BB Squeeze Ended | Range Expansion | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 3.49% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 2.12% | |
| Bollinger Band Squeeze | Range Contraction | 2.12% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 2.12% | |
| Inside Day | Range Contraction | 2.12% | |
| Gapped Up | Strength | 2.12% | |
| Upper Bollinger Band Touch | Strength | 2.12% |
| Alert | Time |
|---|---|
| Upper Bollinger Band Resistance | 1 day ago |
| Rose Above Previous Day's High | 1 day ago |
| Rose Above Upper Bollinger Band | 1 day ago |
| Outside Day | 1 day ago |
| Up 3% | 1 day ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/08/2024
Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. It is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Acute Myeloid Leukemia Gene Therapy Leukemia Central Nervous System Disorders Nervous System Disorders Antitrypsin Deficiency Sickle Cell Disease Acute Leukemia Acute Lymphoblastic Leukemia Thalassemia Beta Thalassemia Glycogen Storage Disorder
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Acute Myeloid Leukemia Gene Therapy Leukemia Central Nervous System Disorders Nervous System Disorders Antitrypsin Deficiency Sickle Cell Disease Acute Leukemia Acute Lymphoblastic Leukemia Thalassemia Beta Thalassemia Glycogen Storage Disorder
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 49.5 |
| 52 Week Low | 16.95 |
| Average Volume | 1,375,219 |
| 200-Day Moving Average | 26.69 |
| 50-Day Moving Average | 27.84 |
| 20-Day Moving Average | 22.79 |
| 10-Day Moving Average | 23.17 |
| Average True Range | 1.58 |
| RSI (14) | 50.98 |
| ADX | 21.55 |
| +DI | 24.82 |
| -DI | 20.38 |
| Chandelier Exit (Long, 3 ATRs) | 21.40 |
| Chandelier Exit (Short, 3 ATRs) | 25.59 |
| Upper Bollinger Bands | 24.85 |
| Lower Bollinger Band | 20.73 |
| Percent B (%b) | 0.94 |
| BandWidth | 18.08 |
| MACD Line | -0.89 |
| MACD Signal Line | -1.50 |
| MACD Histogram | 0.6047 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 27.05 | ||||
| Resistance 3 (R3) | 26.86 | 25.86 | 26.65 | ||
| Resistance 2 (R2) | 25.86 | 25.24 | 25.96 | 26.51 | |
| Resistance 1 (R1) | 25.24 | 24.86 | 25.55 | 25.43 | 26.37 |
| Pivot Point | 24.24 | 24.24 | 24.40 | 24.34 | 24.24 |
| Support 1 (S1) | 23.62 | 23.62 | 23.93 | 23.81 | 22.87 |
| Support 2 (S2) | 22.62 | 23.24 | 22.72 | 22.73 | |
| Support 3 (S3) | 22.00 | 22.62 | 22.60 | ||
| Support 4 (S4) | 22.19 |
